STOCK TITAN

Arteris, Inc. SEC Filings

AIP NASDAQ

Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Arteris, Inc. filings document a semiconductor technology business built around System IP for SoC and chiplet design. Its 8-K reports cover quarterly and annual operating results, financial-condition updates, guidance exhibits, customer shipment milestones, royalty trends and product portfolio disclosures for network-on-chip interconnect IP, SoC integration automation software and hardware security assurance.

The company’s proxy materials cover board elections, executive compensation, equity incentive arrangements and stockholder voting matters. They also describe governance and business context for Arteris’ markets, including automotive, artificial intelligence and machine learning, 5G communications, data centers, edge computing, enterprise and consumer electronics.

Filing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
annual report
-
Rhea-AI Summary

Arteris, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 2, 2026 to elect three Class II directors and ratify Deloitte & Touche LLP as independent auditor for 2026.

The company highlights continued growth since its 2021 IPO, reaching $70 in revenue in 2025 with customers shipping over 4 billion SoCs containing Arteris system IP, and expanding its SoC integration automation products. In January 2026 Arteris acquired Cycuity, Inc., adding semiconductor cybersecurity verification technology.

The record date is April 9, 2026, when 46,092,618 shares of common stock were outstanding. The board has seven members, a classified structure, and a lead independent director, and reports continued use of performance-based bonuses, equity awards and a formal clawback and insider trading policy. Arteris remains an “emerging growth company” with scaled executive compensation disclosure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
proxy
-
Filing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Filing
Rhea-AI Summary

AIP filing a Form 144 notice reporting proposed sales of 90,000 shares of Common stock and a series of recent 10b5-1 dispositions. The excerpt lists multiple sale dates and amounts, including 106,031 and 73,610 shares on March and February 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Arteris, Inc. Chief Operating Officer Laurent R. Moll executed an open-market sale of common stock. On April 14, 2026, he sold 13,448 shares at a weighted average price of $20.0313 per share in multiple transactions.

After this sale, he directly holds 265,530 shares of Arteris common stock. The transaction was carried out under a Rule 10b5-1 trading plan that he adopted on March 12, 2026, indicating the sales were pre-scheduled rather than opportunistic. Individual trade prices ranged from $19.90 to $20.22 per share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Arteris, Inc. director Raman Chitkara sold shares in an open-market transaction. On this date, he sold 5,000 shares of common stock at a weighted average price of $20.0508 per share, with individual sale prices ranging from $20.00 to $20.13. After the sale, he directly holds 152,867 shares, indicating the transaction represents a small portion of his overall position.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Filing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Arteris, Inc. Chief Operating Officer Laurent R. Moll reported small open-market sales of company stock under a pre-set trading plan. He sold a total of 1,993 shares of common stock at a weighted average price around $19.90 per share and continues to hold 278,979 shares directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Laurent Moll reported securities transactions via a Form 144, listing Restricted Stock Units and recent sales executed under a 10b5-1 plan. The filing cites an RSU grant dated 03/15/2022 and three sales: 04/02/2026 (5,602 shares, $98,890.99), 04/06/2026 (1,552 shares, $28,292.96), and 04/10/2026 (990 shares, $19,701.00).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

AIP notice of proposed sales of Common Stock under Rule 144 and a 10b5-1 plan. The filing lists two recent planned sales: 1,552 shares on 04/06/2026 (value $28,292.96) and 5,602 shares on 04/02/2026 (value $98,890.99).

The record also references Restricted Stock Units dated 03/15/2022 as the source of shares. The filing is a notice of intent to sell and does not itself report completed market transactions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other

FAQ

How many Arteris (AIP) SEC filings are available on StockTitan?

StockTitan tracks 188 SEC filings for Arteris (AIP), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Arteris (AIP)?

The most recent SEC filing for Arteris (AIP) was filed on April 21, 2026.